Genix Pharmaceuticals Corporation
GENPF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -67.2% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $0 | $0 | -$1 | -$1 |
| % Margin | 32% | 26.4% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $2 |
| Operating Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -5,949.2% | -7,134.5% | – | – |
| Other Income/Exp. Net | $0 | -$4 | -$0 | -$1 |
| Pre-Tax Income | -$0 | -$4 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$4 | -$1 | -$2 |
| % Margin | -1,806.9% | -35,600.3% | – | – |
| EPS | -0.001 | -0.074 | -0.018 | -0.028 |
| % Growth | 98.4% | -309.9% | 35.1% | – |
| EPS Diluted | -0.001 | -0.074 | -0.018 | -0.028 |
| Weighted Avg Shares Out | 59 | 59 | 59 | 59 |
| Weighted Avg Shares Out Dil | 59 | 59 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | $0 | -$4 | -$0 | -$1 |
| % Margin | 1,211.3% | -30,743.3% | – | – |